The New England Journal of Medicine, the world's most influential and widely read medical periodical, features a study this week about a Phase 2 clinical trial of VX-770, an oral drug in development that targets the root cause of cystic fibrosis.
Site Search
Showing 1 - 10 of 51 results
News
|
May 6, 2011
|
1 min read
News
|
Nov. 8, 2011
|
2 min read
News
|
Nov. 17, 2010
|
3 min read
News
|
Sept. 16, 2008
|
1 min read
News
|
April 11, 2008
|
1 min read
News
|
Aug. 20, 2008
|
1 min read
News
|
Aug. 11, 2014
|
2 min read
The U.S. Food and Drug Administration approved the use of lumacaftor/ivacaftor (Orkambi®) today for children with cystic fibrosis ages 2 to 5 who have two copies of the F508del mutation.
News
|
Aug. 7, 2018
|
3 min read
News
|
March 4, 2011
|
2 min read
News
|
Oct. 25, 2011
|
2 min read